Mutational Analysis of Driver and Non-driver Mutations of Philadelphia Chromosome-negative Myeloproliferative Neoplasms; Diagnosis and Recent Advances in Treatment

Table 2. Simplified 2022 WHO diagnosis criteria for ETand post-ET MF; Adapted from: [6, 104].

ET	Post-ET MF
Major Criteria:	Required Criteria:
Increased platelet count ≥ 450×10⁹/L	Previously diagnosed ET
Proliferation of enlarged, mature megakaryocytes with hyperlobulated nuclei.	Grade 2 or 3 bone marrow fibrosis.
Criteria for BCR-ABL1, CML, PV, PMF, MDS or other myeloid neoplasms not met.	Additional Criteria:
Presence of JAK2 (< 1% sensitivity assay). CALR or MPL (1-3% sensitivity assay) mutations.	Anemia and decreased hemoglobin >2g/Dl from baseline.Leukoerythroblastosis.
Minor Criteria:	New or increased palpable splenomegaly >5 cm from baseline
Presence of clonal marker (eg, ASXL1, EZH2, TET2, IDH1/IDH2, SRSF2, SF3B1 mutations) or absence of evidence for reactive thrombocytosis	Increased LDH levels above the reference range.
Requirements for diagnosis:	Presence of at least 2 of the following: unexplained pyrexia (>37.5℃), weight loss (>10% in 6 months), night sweats.
All 4 major OR first 3 majors + minor criterion	Requirement for diagnosis:
	All required criteria + 2 or more additional criteria